These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38171846)

  • 1. Cross-Neutralization Activities of Antibodies against 18 Lyssavirus Glycoproteins.
    Inoue Y; Kaku Y; Harada M; Ishijima K; Kuroda Y; Tatemoto K; Virhuez-Mendoza M; Nishino A; Yamamoto T; Inoue S; Matsuu A; Maeda K
    Jpn J Infect Dis; 2024 May; 77(3):169-173. PubMed ID: 38171846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-neutralization of antibodies induced by vaccination with Purified Chick Embryo Cell Vaccine (PCECV) against different Lyssavirus species.
    Malerczyk C; Freuling C; Gniel D; Giesen A; Selhorst T; Müller T
    Hum Vaccin Immunother; 2014; 10(10):2799-804. PubMed ID: 25483634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toward the Development of a Pan-Lyssavirus Vaccine.
    Ben Hamed S; Myers JF; Chandwani A; Wirblich C; Kurup D; Paran N; Schnell MJ
    Viruses; 2024 Jul; 16(7):. PubMed ID: 39066269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolation and Characterization of Cross-Reactive Human Monoclonal Antibodies That Potently Neutralize Australian Bat Lyssavirus Variants and Other Phylogroup 1 Lyssaviruses.
    Weir DL; Coggins SA; Vu BK; Coertse J; Yan L; Smith IL; Laing ED; Markotter W; Broder CC; Schaefer BC
    Viruses; 2021 Mar; 13(3):. PubMed ID: 33804519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antigenic site changes in the rabies virus glycoprotein dictates functionality and neutralizing capability against divergent lyssaviruses.
    Evans JS; Selden D; Wu G; Wright E; Horton DL; Fooks AR; Banyard AC
    J Gen Virol; 2018 Feb; 99(2):169-180. PubMed ID: 29300155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serological Evidence of Lyssaviruses among Bats on Southwestern Indian Ocean Islands.
    Mélade J; McCulloch S; Ramasindrazana B; Lagadec E; Turpin M; Pascalis H; Goodman SM; Markotter W; Dellagi K
    PLoS One; 2016; 11(8):e0160553. PubMed ID: 27501458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utilisation of Chimeric Lyssaviruses to Assess Vaccine Protection against Highly Divergent Lyssaviruses.
    Evans JS; Wu G; Selden D; Buczkowski H; Thorne L; Fooks AR; Banyard AC
    Viruses; 2018 Mar; 10(3):. PubMed ID: 29543715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of rabies vaccines in dogs and cats and protection in a mouse model against European bat lyssavirus type 2.
    Nokireki T; Jakava-Viljanen M; Virtala AM; Sihvonen L
    Acta Vet Scand; 2017 Oct; 59(1):64. PubMed ID: 28969696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment of serological neutralizing tests using pseudotyped viruses for comprehensive detection of antibodies against all 18 lyssaviruses.
    Inoue Y; Kaku Y; Harada M; Ishijima K; Kuroda Y; Tatemoto K; Virhuez-Mendoza M; Nishino A; Yamamoto T; Park ES; Inoue S; Matsuu A; Maeda K
    J Vet Med Sci; 2024 Jan; 86(1):128-134. PubMed ID: 38092389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Lyssavirus glycoprotein: A key to cross-immunity.
    Buthelezi SG; Dirr HW; Chakauya E; Chikwamba R; Martens L; Tsekoa TL; Stoychev SH; Vandermarliere E
    Virology; 2016 Nov; 498():250-256. PubMed ID: 27614701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenicity and Immunogenicity of Recombinant Rabies Viruses Expressing the Lagos Bat Virus Matrix and Glycoprotein: Perspectives for a Pan-Lyssavirus Vaccine.
    Kgaladi J; Faber M; Dietzschold B; Nel LH; Markotter W
    Trop Med Infect Dis; 2017 Aug; 2(3):. PubMed ID: 30270894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lyssavirus Vaccine with a Chimeric Glycoprotein Protects across Phylogroups.
    Fisher CR; Lowe DE; Smith TG; Yang Y; Hutson CL; Wirblich C; Cingolani G; Schnell MJ
    Cell Rep; 2020 Jul; 32(3):107920. PubMed ID: 32697993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-Protection of Inactivated Rabies Vaccines for Veterinary Use against Bat Lyssaviruses Occurring in Europe.
    Servat A; Wasniewski M; Cliquet F
    Viruses; 2019 Oct; 11(10):. PubMed ID: 31614675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-protective and cross-reactive immune responses to recombinant vaccinia viruses expressing full-length lyssavirus glycoprotein genes.
    Weyer J; Kuzmin IV; Rupprecht CE; Nel LH
    Epidemiol Infect; 2008 May; 136(5):670-8. PubMed ID: 17588277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross reactive antigenicity in orally vaccinated foxes and raccoon dogs against European Bat Lyssavirus type 1 and 2.
    Müller T; Selhorst T; Burow J; Schameitat A; Vos A
    Dev Biol (Basel); 2006; 125():195-204. PubMed ID: 16878477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibodies induced by vaccination with purified chick embryo cell culture vaccine (PCECV) cross-neutralize non-classical bat lyssavirus strains.
    Malerczyk C; Selhorst T; Tordo N; Moore S; Müller T
    Vaccine; 2009 Aug; 27(39):5320-5. PubMed ID: 19615958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Taiwan Bat Lyssavirus: In Vitro and In Vivo Assessment of the Ability of Rabies Vaccine-Derived Antibodies to Neutralise a Novel Lyssavirus.
    Shipley R; Wright E; Smith SP; Selden D; Fooks AR; Banyard AC
    Viruses; 2022 Dec; 14(12):. PubMed ID: 36560754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies against Duvenhage virus in insectivorous bats in Swaziland.
    Markotter W; Monadjem A; Nel LH
    J Wildl Dis; 2013 Oct; 49(4):1000-3. PubMed ID: 24502729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative pathogenesis of different phylogroup I bat lyssaviruses in a standardized mouse model.
    Klein A; Eggerbauer E; Potratz M; Zaeck LM; Calvelage S; Finke S; Müller T; Freuling CM
    PLoS Negl Trop Dis; 2022 Jan; 16(1):e0009845. PubMed ID: 35041652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantification of Lyssavirus-Neutralizing Antibodies Using Vesicular Stomatitis Virus Pseudotype Particles.
    Moeschler S; Locher S; Conzelmann KK; Krämer B; Zimmer G
    Viruses; 2016 Sep; 8(9):. PubMed ID: 27649230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.